SIGA Technologies, Inc. - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the sale of TPOXX® (tecovirimat), an antiviral drug for smallpox, to the U.S. Government and international entities. The company operates in a single segment and relies heavily on long-term procurement contracts with the U.S. Biomedical Advanced Research and Development Authority (BARDA).
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenues | $7.04 million | $25.43 million |
| Net (Loss)/Income | ($0.41) million | $10.28 million |
| Operating (Loss)/Income | ($2.26) million | $11.28 million |
| Cash and Cash Equivalents | $162.27 million | $143.87 million |
| Net Cash Provided by Operating Activities | $7.06 million | ($6.12) million |
| Inventory | $59.06 million | $49.56 million |
| Total Liabilities | $30.93 million | $28.53 million |
Note: The filing does not explicitly state a gross margin percentage for the quarter, though management estimates IV TPOXX gross margins under the BARDA contract to be less than 40%.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by approximately 72% year-over-year, driven primarily by a lack of product delivery revenue to the U.S. Government in Q1 2025 compared to $14.7 million in Q1 2024. International sales also decreased from $8.0 million to $5.8 million.
- Profitability Shift: The company reported a net loss of $0.41 million in Q1 2025, a reversal from the $10.28 million net income in Q1 2024. This was due to lower revenues and increased operating expenses.
- Expense Trends: Selling, general, and administrative (SG&A) expenses decreased by $2.2 million, largely due to lower international promotion fees. Conversely, Research and Development (R&D) expenses increased by $0.4 million due to IT enhancements and headcount increases.
- Balance Sheet: Inventory increased by $9.5 million, reflecting manufacturing activities. Accounts receivable decreased by $14.0 million as the company collected significant outstanding balances from prior periods.
Outlook, Commentary, and Risks
- BARDA Contract Updates: On March 26, 2025, BARDA exercised an option for $25.6 million of IV TPOXX. On April 8, 2025, the contract was modified to increase total contemplated payments to $616.8 million. Cumulative exercised options now total $545.2 million.
- Product Deliveries: In April 2025 (subsequent to the quarter end), the company delivered approximately $53 million of oral TPOXX and $9 million of IV TPOXX to the Strategic National Stockpile.
- Clinical Trial Results: Two major randomized clinical trials for TPOXX in treating mpox (PALM 007 and STOMP) did not meet their primary endpoints for efficacy in time to lesion resolution. The company believes ongoing trials are likely to yield similar results, though safety profiles remain strong.
- Dividend Declaration: On April 8, 2025, the Board declared a special cash dividend of $0.60 per share, payable May 15, 2025.
- Risks: Key risks include the uncertainty of future government contract exercises, the potential impact of tariffs on supply chain costs, and the failure of mpox clinical trials to demonstrate efficacy, which could limit commercial opportunities outside of government stockpiling.
Investor Verification Checklist
- Verify the timing and volume of future BARDA option exercises and product deliveries to the Strategic National Stockpile.
- Monitor the impact of the mpox clinical trial failures on international commercial sales and potential label expansions.
- Confirm the company's ability to maintain liquidity following the declaration of the $0.60 per share special dividend.
- Review the status of the Supplemental NDA submission for smallpox post-exposure prophylaxis (PEP), targeted for submission within the next 12 months.
- Assess the impact of potential tariff changes on the cost of manufacturing and supply chain operations.